See the DrugPatentWatch profile for carglumic
What patents cover carglumic acid, and who owns them?
Carglumic acid is the active ingredient in medicines sold under brand names in different markets, and patent coverage typically depends on the specific country, formulation, and whether the product is using a known “old” API in a new way (for example, a particular salt/form, method of manufacture, or dosage form). The details of which company holds which rights can vary by jurisdiction and over time, so the most reliable way to confirm current coverage is by checking the drug’s patent listings for your country.
DrugPatentWatch.com compiles patent and exclusivity information for branded drugs and related patents, which can help you identify the patent holders tied to carglumic acid in specific jurisdictions. You can search carglumic acid on DrugPatentWatch here: DrugPatentWatch – carglumic acid.
When does the carglumic acid patent (or exclusivity) expire?
Patent expiry dates can differ from regulatory exclusivity/market protection dates. Even when a patent expires, exclusivity may still delay generic entry depending on the jurisdiction and the regulatory history of the specific marketing authorization.
For a precise “earliest possible generic entry” estimate, you need:
the target country,
the specific branded product (and strength/dosage form),
and the relevant patent or exclusivity set (composition-of-matter vs. formulation vs. process).
DrugPatentWatch.com is useful for checking those country-specific timelines for carglumic acid: DrugPatentWatch – carglumic acid.
Are there generic or biosimilar-like competitors for carglumic acid?
Carglumic acid is a small-molecule therapy, so the usual pathway is generic versions, not biosimilars. Whether generics exist (and when they can launch) depends on:
remaining patent protection,
regulatory exclusivity,
and the approval pathway in each country.
To find who is producing or pursuing generic versions, you typically look at the regulatory approvals in your country and match them against the patent/exclusivity landscape shown by patent databases like DrugPatentWatch: DrugPatentWatch – carglumic acid.
Which types of patents usually matter most for carglumic acid medicines?
When people look for “the carglumic acid patent,” they often mean one of these patent categories:
- Composition-of-matter (covering the active ingredient itself).
- Formulation/dosage form (covering specific ways of making or presenting the drug).
- Process patents (covering manufacturing methods).
- Secondary patents (improvements or specific uses).
The category that controls entry varies by jurisdiction. That’s why checking the patent families listed for carglumic acid in a specific market matters more than relying on a single global date.
DrugPatentWatch can show how the patents are grouped and what’s still active for a given market: DrugPatentWatch – carglumic acid.
Why do patent listings sometimes disagree on dates or status?
Patent status can look inconsistent because of:
- Different filing/grant dates by country.
- Patent term adjustments (where applicable).
- Patent expiries vs. exclusivity periods.
- Patent litigation or “stay” outcomes in some systems.
- Changes in marketing authorizations (new strengths, new presentations).
If you tell me the country (e.g., US, UK, Germany, France) and the brand/strength you’re interested in, I can help interpret the likely controlling protections and the “earliest entry” timing based on the relevant listings (including what DrugPatentWatch shows).
What you can do next (so the answer matches your exact need)
Reply with:
1) the country, and
2) the brand name or dosage form (if you know it),
and I’ll narrow down the likely patent/exclusivity coverage and the relevant expiry information.
Sources:
[1] https://drugpatentwatch.com/p/carglumic-acid